XLO

XLO

Xilio Development Inc

Net 10.66%top 1%Rev 22.20%top 1%Net income grew 100% of yearsRevenue grew 100% of years1Y
Hold

Xilio Development Inc is a biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies, including bispecific antibodies and cytokines, aimed at improving cancer treatment outcomes while minimizing systemic side effects.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$923today

Score Overview

1 Year
Scoreโ€”
Net Growth10.66%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth22.20%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-80.81%
Net Trend57%
Net Income Consistency
Rev Growthโ€”
Rev Trend43%
Revenue Consistency

See the full market ranking โ†’

Xilio Development Inc fundamental performance

Across Xilio Development Inc's full reported history, from 2019 to 2025, revenue grew from $ 0.00 to $ 43M and net income went from -$ 17M to -$ 35M. Revenue increased in 43% of the years measured; net income in 57%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 9.05โ€”
1 Year2025-08-12
$ 9.80-7.65%
All Time2021-10-22
$ 224.00-95.96%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 53M-$ 31M$ 150M
2025$ 43M-$ 35M$ 137M
2024$ 6M-$ 58M$ 55M
2023$ 0.00-$ 76M$ 44M
2022$ 0.00-$ 87M$ 120M
IPO2021$ 0.00-$ 74M$ 198M
2020$ 0.00-$ 55M$ 19M
2019$ 0.00-$ 17M$ 48M

Explore beyond XLO

You're looking at Xilio Development Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies